CTI is developing medicines to help treat your cancer while maintaining your quality of life.
Pixantrone is marketed by CTI in the EU as Pixuvri®.Summary of Product Characteristics and Package Insert
Learn about our potential treatments for non-Hodgkin Lymphoma.See Phase 3 Pipeline
Learn about our potential treatments for Acute Myeloid Leukemia (AML), Myelodysplasia (MDS).See Phase 1 Pipeline
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI® (pixantrone) in Germany
Cell Therapeutics Receives $5 Million Milestone Payment for TRISENOX®
BAXTER AND CELL THERAPEUTICS ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE PACRITINIBLearn more
Our late-stage development pipeline addresses a full complement of blood-related cancers.learn about our oncology pipeline